AstraZeneca's Imfinzi Scores First Early Lung Cancer Approval

17 Feb 2018

• By Emily Hayes

Unlike other indications PD-1/L1 inhibitors are shooting for, Stage III non-small cell lung cancer is an untapped market and AstraZeneca will have the space to itself for a while.

Instagram style filter silhouette of a successful woman or girl arms raised celebrating at sunrise or sunset in front of the New York City Skyline

US FDA approval of AstraZeneca PLC's Imfinzi (durvalumab) for non-small cell lung cancer is important in two big respects – it is the drug's first clearance in this valuable tumor type and it is the first in such an early line of therapy for a PD-1/L1 inhibitor.

FDA announced approval of Imfinzi on Feb. 16 for patients with Stage III non-small cell lung cancer (NSCLC) whose tumors...